Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice

Programmed cell death protein-1/ligand 1 (PD-1/L1) targeted immune checkpoint inhibitors have become the focus of tumor treatment due to their promising efficacy. Currently, several PD-1/PD-L1 inhibitors have been approved for clinical practice with several more in clinical trials. Notably, based on...

Full description

Bibliographic Details
Main Authors: Yu Chen, Yanqing Pei, Jingyu Luo, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Immunology
Subjects:
PD-1 inhibitors
PD-L1 inhibitors
comparison
differences
optimal treatment
efficacy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01088/full

Similar Items

Similar Items